SAR156597

Sanofi · Phase 2 active Small molecule

At a glance

Generic name	SAR156597
Also known as	Romilkimab
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (PHASE2)
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis (PHASE2)
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SAR156597 CI brief — competitive landscape report
SAR156597 updates RSS · CI watch RSS
Sanofi portfolio CI